Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +6 vs. previous quarter
- 13
- 13F valueReported value at the end of Q2 2026
- $158.0K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DRMA, Q2 2026
No superinvestor reported holding DRMA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Dermata Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 (view filing) | Jun 16 | Same day | Scott Kathleen D.Director | SSale | −11 | $1.19 | −$13.09 | −100.0%0 after | |
| Mar 17, 2026 (view filing) | Feb 17 | 28 daysLate | Bedoya-Toro Munera Maria ESVP, Regulatory Affairs | PPurchase | +1.00K | $1.27 | +$1.27K | +8,333.3%1.01K after | |
| Nov 26, 2021 (view filing) | Nov 23 | 3 days | Proehl Gerald TPresident, CEO and Chairman | PPurchase | +20.0K | $2.40 | +$48.0K | +50.6%59.5K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Hale David FDirector, 10% Owner | PPurchase | +35.7K | – | – | New position35.7K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Hale David FDirector, 10% Owner | PPurchase | +35.7K | – | – | –35.7K after | Derivative |
| Aug 17, 2021 (view filing) | Aug 16-17 | 1 day | Proehl Gerald TPresident, CEO and Chairman | PPurchase | +152.9K | $4.96 | +$49.6K | New position152.9K after | 2 lots |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Proehl Gerald TPresident, CEO and Chairman | PPurchase | +142.9K | – | – | –142.9K after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Dermata Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 20,203 | $26.1K | 0.00% | −28,131−58.2% | Reduced |
| Welch & Forbes LLC | 20,000 | $25.8K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 18,747 | $24.2K | 0.00% | +18,747 | New |
| UBS Group AG | 16,796 | $21.7K | 0.00% | −18,812−52.8% | Reduced |
| Susquehanna International Group, LLP | 15,989 | $20.6K | 0.00% | +15,989 | New |
| XTX Topco Ltd | 14,787 | $19.1K | 0.00% | +14,787 | New |
| Advisory Alpha, LLC | 10,000 | $12.9K | 0.00% | +10,000 | New |
| Tower Research Capital LLC (TRC) | 3,860 | $4.98K | 0.00% | +3,144+439.1% | Added |
| MCF Advisors LLC | 1,732 | $2.23K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 270 | $348 | 0.00% | +270 | New |